Retrospective Review Investigating the Efficacy of the Gray/Campbell Migraine Injection Protocol for OnabotulinumtoxinA (A Modified PREEMPT Injection Paradigm for Chronic Migraine Treatment)
Chronic migraine is a potentially debilitating condition that can be detrimental to someone’s quality of life. Clinical data has proven OnabotulinumtoxinA (BoNT-A) to be an effective prophylactic treatment for chronic headache types, and it is now regularly employed by headache treatment centers. The PREEMPT injection protocol has become the standard treatment regimen surrounding Botox injections for chronic migraine treatment since it was granted approval by the FDA in 2010. This retrospective chart review of patients treated for chronic migraine at Maine Comprehensive Pain Management in Scarborough, Maine, presents an alteration to the standard PREEMPT injection paradigm that reinforces the efficacy of Botox for chronic migraine treatment. We will discuss our Modified PREEMPT injection paradigm, which yields a positive clinical response rate of 95% of patients achieving at least 50% improvement in their migraine headaches. This appears to be the highest established response rate in the literature to date.
References
[1]
Szok, D., Csáti, A., Vécsei, L. and Tajti, J. (2015) Treatment of Chronic Migraine with Onabotulinumtoxina: Mode of Action, Efficacy and Safety. Toxins, 7, 2659-2673. https://doi.org/10.3390/toxins7072659
[2]
Lanteri-Minet, M., Ducros, A., Francois, C., Olewinska, E., Nikodem, M. and Dupont-Benjamin, L. (2022) Effectiveness of Onabotulinumtoxina (BOTOX) for the Preventive Treatment of Chronic Migraine: A Meta-Analysis on 10 Years of Real-World Data. Cephalalgia, 42, 1543-1564. https://doi.org/10.1177/03331024221123058
[3]
Zhang, Y., Kong, Q., Chen, J., Li, L., Wang, D. and Zhou, J. (2015) International Classification of Headache Disorders 3rd Edition Beta-Based Field Testing of Vestibular Migraine in China: Demographic, Clinical Characteristics, Audiometric Findings and Diagnosis Statues. Cephalalgia, 36, 240-248. https://doi.org/10.1177/0333102415587704
[4]
May, A. and Schulte, L.H. (2016) Chronic Migraine: Risk Factors, Mechanisms and Treatment. Nature Reviews Neurology, 12, 455-464. https://doi.org/10.1038/nrneurol.2016.93
[5]
Buse, D.C., Manack, A., Serrano, D., Turkel, C. and Lipton, R.B. (2010) Sociodemographic and Comorbidity Profiles of Chronic Migraine and Episodic Migraine Sufferers. Journal of Neurology, Neurosurgery & Psychiatry, 81, 428-432. https://doi.org/10.1136/jnnp.2009.192492
[6]
Carod-Artal, F.J. (2014) Tackling Chronic Migraine: Current Perspectives. Journal of Pain Research, 2014, 185-194. https://doi.org/10.2147/jpr.s61819
[7]
Mathew, N.T. (2011) Pathophysiology of Chronic Migraine and Mode of Action of Preventive Medications. Headache: The Journal of Head and Face Pain, 51, 84-92. https://doi.org/10.1111/j.1526-4610.2011.01955.x
[8]
Weiller, C., May, A., Limmroth, V., Jüptner, M., Kaube, H., Schayck, R.V., et al. (1995) Brain Stem Activation in Spontaneous Human Migraine Attacks. Nature Medicine, 1, 658-660. https://doi.org/10.1038/nm0795-658
[9]
Welch, K.M.A., Nagesh, V., Aurora, S.K. and Gelman, N. (2001) Periaqueductal Gray Matter Dysfunction in Migraine: Cause or the Burden of Illness? Headache: The Journal of Head and Face Pain, 41, 629-637. https://doi.org/10.1046/j.1526-4610.2001.041007629.x
[10]
Kępczyńska, K. and Domitrz, I. (2022) Botulinum Toxin—A Current Place in the Treatment of Chronic Migraine and Other Primary Headaches. Toxins, 14, Article 619. https://doi.org/10.3390/toxins14090619
[11]
Robertson, C., Robertson, C. and Garza, I. (2012) Critical Analysis of the Use of Onabotulinumtoxina (Botulinum Toxin Type A) in Migraine. Neuropsychiatric Disease and Treatment, 2012, 35-48. https://doi.org/10.2147/ndt.s17923
[12]
Aurora, S., Dodick, D., Turkel, C., DeGryse, R., Silberstein, S., Lipton, R., et al. (2010) Onabotulinumtoxina for Treatment of Chronic Migraine: Results from the Double-Blind, Randomized, Placebo-Controlled Phase of the PREEMPT 1 Trial. Cephalalgia, 30, 793-803. https://doi.org/10.1177/0333102410364676
[13]
Diener, H., Dodick, D., Aurora, S., Turkel, C., DeGryse, R., Lipton, R., et al. (2010) Onabotulinumtoxina for Treatment of Chronic Migraine: Results from the Double-Blind, Randomized, Placebo-Controlled Phase of the PREEMPT 2 Trial. Cephalalgia, 30, 804-814. https://doi.org/10.1177/0333102410364677
[14]
Burstein, R., Blumenfeld, A.M., Silberstein, S.D., Manack Adams, A. and Brin, M.F. (2020) Mechanism of Action of Onabotulinumtoxina in Chronic Migraine: A Narrative Review. Headache: The Journal of Head and Face Pain, 60, 1259-1272. https://doi.org/10.1111/head.13849
[15]
Blumenfeld, A., Silberstein, S.D., Dodick, D.W., Aurora, S.K., Turkel, C.C. and Binder, W.J. (2010) Method of Injection of Onabotulinumtoxina for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program. Headache: The Journal of Head and Face Pain, 50, 1406-1418. https://doi.org/10.1111/j.1526-4610.2010.01766.x
[16]
Tepper, D. (2014) Onabotulinumtoxin A (Botox). Headache: The Journal of Head and Face Pain, 54, 787-788. https://doi.org/10.1111/head.12342
[17]
Olesen, J., et al. (2018) The International Classification of Headache Disorders. 3rd Edition, International Headache Society, 11-12.
[18]
Khalil, M., Zafar, H.W., Quarshie, V. and Ahmed, F. (2014) Prospective Analysis of the Use of Onabotulinumtoxina (BOTOX) in the Treatment of Chronic Migraine; Real-Life Data in 254 Patients from Hull, UK. The Journal of Headache and Pain, 15, 1-9. https://doi.org/10.1186/1129-2377-15-54
[19]
Silberstein, S.D., Dodick, D.W., Aurora, S.K., Diener, H., DeGryse, R.E., Lipton, R.B., et al. (2014) Per Cent of Patients with Chronic Migraine Who Responded per Onabotulinumtoxina Treatment Cycle: Preempt. Journal of Neurology, Neurosurgery & Psychiatry, 86, 996-1001. https://doi.org/10.1136/jnnp-2013-307149
[20]
Chatchawan, U., Thongbuang, S. and Yamauchi, J. (2019) Characteristics and Distributions of Myofascial Trigger Points in Individuals with Chronic Tension-Type Headaches. Journal of Physical Therapy Science, 31, 306-309. https://doi.org/10.1589/jpts.31.306
[21]
Ernest, E. and Ernest, M. (2006) Splenius Capitis Muscle Syndrome. Practical Pain Management, 6.
[22]
Klein, D. (2009) Muscle Tension Headache: Splenius Capitis Syndrome. Pain Doctor Type Pad.
[23]
Moore, K.L., Dalley, A.F. and Agur, A.M.R. (2014) Clinically Orientated Anatomy. 7th Edition, Lippincott Williams & Wilkins.
